Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Phar
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||43.07%||Sales Growth - Q/Q||27.68%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-80.97%||ROE||156.1%||ROI||-102.16%|
|Current Ratio||2.13||Quick Ratio||2.09||Long Term Debt/Equity||5.49||Debt Ratio||-0.4|
|Gross Margin||91.55%||Operating Margin||-615.77%||Net Profit Margin||-774.12%||Dividend Payout Ratio|
|Cash From Financing Activities||-220 K||Cash From Investing Activities||49.9 M||Cash From Operating Activities||-45.09 M||Gross Profit||8.62 M|
|Net Profit||-35.17 M||Operating Profit||-22.76 M||Total Assets||282.93 M||Total Current Assets||125.04 M|
|Total Current Liabilities||58.68 M||Total Debt||368.43 M||Total Liabilities||429.69 M||Total Revenue||9.39 M|
|High 52 week||29.78||Low 52 week||13.65||Last close||22.37||Last change||3.95%|
|RSI||42.86||Average true range||0.95||Beta||1.53||Volume||4.05 M|
|Simple moving average 20 days||0.6%||Simple moving average 50 days||3.34%||Simple moving average 200 days||13.82%|
|Performance Week||0.49%||Performance Month||-1.19%||Performance Quart||26.6%||Performance Half||23.32%|
|Performance Year||-23.13%||Performance Year-to-date||13.73%||Volatility daily||2.27%||Volatility weekly||5.07%|
|Volatility monthly||10.4%||Volatility yearly||36.03%||Relative Volume||263.48%||Average Volume||4.26 M|
|New High||New Low|
2019-06-10 08:07:52 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-06-07 06:00:00 | Exelixis Bets on Breakthroughs in Oncology
2019-06-06 13:55:00 | Top 5 Stocks in the Fight Against Cancer
2019-06-04 08:06:40 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-05-31 09:31:01 | Why Is Exelixis EXEL Down 1% Since Last Earnings Report?
2019-05-30 15:09:37 | Is Exelixis, Inc.'s NASDAQ:EXEL CEO Being Overpaid?
2019-05-29 16:05:00 | Exelixis Announces Webcasts of Investor Conference Presentations in June 2019
2019-05-24 08:25:12 | Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
2019-05-22 09:37:01 | Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
2019-05-15 09:27:01 | Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
2019-05-14 16:05:00 | Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019
2019-05-14 07:49:00 | These 3 Value Stocks Are Absurdly Cheap Right Now
2019-05-13 06:00:00 | Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® Esaxerenone Tablets in Japan
2019-05-10 07:32:02 | Jim Cramer Weighs In On Zebra Technologies, Exelixis And More
2019-05-07 09:00:00 | Where Will Gilead Sciences Spend Its Cash?
2019-05-07 08:06:41 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-05-06 15:31:00 | Exelixis Expands Its Sales
2019-05-06 13:08:48 | Estimating The Fair Value Of Exelixis, Inc. NASDAQ:EXEL
2019-05-02 11:21:03 | Exelixis EXEL Earnings & Revenues Beat Estimates in Q1
2019-05-02 02:51:33 | Exelixis Inc EXEL Q1 2019 Earnings Call Transcript
2019-05-02 01:20:55 | Edited Transcript of EXEL earnings conference call or presentation 1-May-19 9:00pm GMT
2019-05-01 18:35:10 | Exelixis EXEL Beats Q1 Earnings and Revenue Estimates
2019-05-01 17:27:50 | Exelixis: 1Q Earnings Snapshot
2019-05-01 16:06:00 | Exelixis Initiating Phase 3 Pivotal Trial COSMIC-313 of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma
2019-05-01 16:05:00 | Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update
2019-04-29 09:17:00 | 2 Incredibly Cheap Value Stocks to Buy Now
2019-04-26 09:43:00 | News Surrounds 3 Small Biotechs, With a Merger Claiming One
2019-04-25 09:42:01 | Exelixis EXEL to Report Q1 Earnings: What's in Store?
2019-04-24 10:33:02 | Analysts Estimate Exelixis EXEL to Report a Decline in Earnings: What to Look Out for
2019-04-23 15:54:00 | Kidney-Cancer Market: Good for Patients, Hard for Investors
2019-04-21 17:54:52 | Did Hedge Funds Drop The Ball On Exelixis, Inc. EXEL ?
2019-04-20 08:00:00 | 3 Cancer Treatment Stocks to Buy in April
2019-04-19 14:12:00 | 5 Top Pharmaceutical Stocks to Buy in 2019
2019-04-17 16:05:00 | Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019
2019-04-16 19:26:11 | ProQR Initiates Dosing in Phase II/III Eye Disorder Study
2019-04-15 14:18:38 | Has Exelixis, Inc. NASDAQ:EXEL Got Enough Cash?
2019-04-11 06:33:06 | Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock
2019-04-09 10:51:13 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-04-05 22:03:02 | Exelixis EXEL Rallies 22.4% YTD: What to Expect Ahead?
2019-04-05 16:05:00 | Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019
2019-04-01 09:25:01 | The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
2019-03-28 08:06:37 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-03-27 10:02:07 | Market Trends Toward New Normal in 3M, Exelixis, Wright Medical Group N.V, MSA Safety Incorporated, Principal Financial Group, and Portland General Electric — Emerging Consolidated Expectations, Analyst Ratings
2019-03-26 08:26:32 | See what the IHS Markit Score report has to say about Exelixis Inc.
2019-03-18 14:26:28 | Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'
2019-03-18 13:06:50 | Signal Says Buy Options Insurance on This Biotech